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Title.  Valdecoxib: The rise and fall of a COX-2 inhibitor 
Abstract 
Introduction: Valdecoxib is a cyclooxygenase 2 (COX-2) selective anti -inflammatory drug.  It 
is associated with a reduced incidence of gastrointestinal complications and is potentially 
useful for patients with rheumatological diseases requiring longer term anti-inflammatory 
treatment.    
Areas covered: Due to a perceived increased risk of thrombotic events, particularly 
cardiovascular hazards and reports of unpredictable, potentially life threatening skin 
reactions, valdecoxib has been voluntarily withdrawn from the market since 2005. This 
review manuscript examines the therapeutic potential and the adverse events of valdecoxib 
utilising a pubmed and web of sciences search to select literature on this subject.   
Expert opinion:  Whilst valdecoxib did have reduced incidence of gastrointestinal 
complications due to a perceived increased risk of thrombotic events it was withdrawn. The 
limitations of the research supporting the withdrawal of this potential are discussed. 
Keywords 
Valdecoxib, COX-2 inhibitor, osteoarthritis, rheumatoid arthritis, cardiovascular side effects 
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1. Overview of the market  
The COX-2 inhibitors were developed with the promise of improved gastro-intestinal safety 
in comparison with non-selective anti-inflammatory agents. These drugs were perceived to 
be of particular use in the treatment of rheumatological diseases where long term anti –
inflammatory drug use, with the combination of other disease modifying drugs,  is still the 
norm. Unfortunately, these agents have been associated with a small but measurable 
increased risk of cardiovascular events which originally lead to the voluntary withdrawal of 
rofecoxib (Vioxx) in 2004 and then valdecoxib in 2005. One coxib, celecoxib (Celebrex) 
remains on the market despite similar findings. 
2.  Introduction to compound 
Inflammation is a prominent component of most local and multisystem musculoskeletal 
diseases.  Though therapies modifying the disease course of autoimmune rheumatological 
diseases are the mainstay of treatment, non-steroidal anti-inflammatory drugs (NSAIDS) and 
cyclooxygenase 2 (COX-2) inhibitors continue to be of value in disease management.  These 
drugs provide pain relief, reduce joint swelling, and moreover are effective in reducing pain 
and regional inflammation in acute sprains, fractures and soft tissue rheumatic disorders. 
The main mediators of inflammation are eicosanoids (prostaglandin, prostacyclin [PGI2], 
thromboxane A2, and leukotrienes) produced from arachidonic acid derived from 
membrane phospholipids (figure 1).  NSAIDs inhibit the fatty acid cyclo-oxygenase (COX) 
enzyme; prostaglandin G/H synthase; resulting in reduced prostaglandin and thromboxane 
production [1].  There are two isoforms of this enzyme: COX-1 is generally believed to be a 
constitutive, housekeeping enzyme present in most tissues; whilst COX-2 is induced by 
pathological processes [2][3].   The inhibition of COX-1 and COX-2 pathways results not only 
in reduced inflammation and anti-pyresis but also in reduced platelet aggregation, a 
propensity to cause gastrointestinal ulceration and perforations, and fluid and sodium 
retention, especially when taken on a chronic basis [4-6] The selective COX-2 inhibitors such 
as valdecoxib were developed with the aim of reducing the untoward side effects of NSAIDS 
whilst preserving its useful anti-inflammatory function.  
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 2.1. Chemistry 
The mechanism of action of valdecoxib is best understood by comprehending the intricacies 
of the prostanoid (PG) and thromboxane synthesis. The first committed step in this process 
is the metabolism of archidonic acid to prostaglandin H by the enzyme prostaglandin H2 
synthetase, also known as cyclo-oxygenase (COX).  The first step, the dioxygenase step, 
incorporates two molecules of oxygen into the arachidonic chain at C11 and C15 positions 
resulting in the formation of the highly unstable endoperoxidase mediator PGG2.  As the 
COX enzymes are bi-functional, these enzymes are capable of peroxidation of this end 
product. The result is the conversion of PGG2 to PGH2, where the PGG2 hydroperoxidase 
group in C15 is transformed to a hydroxy-group PGH2.  Thereafter, PGG2 is subject to other 
isomerases, reductases or synthetases which transforms it to other prostanoids [7].  
Both COX-1 and COX-2 are homodimers in the intracellular membrane. Both of these similar 
isoforms contain a hydrophobic channel into which arachidonic acid or other fatty acid 
substrates can dock in order for oxygenation to occur.  COX 2 contains a bulky side pocket 
which is not present in COX-1 and therefore drugs such as valdecoxib, which contain a bulky 
groups or moieties bind only to COX-2. These COX2 inhibitors then enter the hydrophobic 
channel in these enzymes blocking the entry of the fatty acid substrates.   
Valdecoxib is a diaryl substituted isoxazole, structurally similar to celecoxib, the first COX2 
inhibitor (Figure 3).  Hydroxylamine hydrochloride in the presence of sodium acetate  was 
used to convert deoxybenzamin  to its corresponding oxime [8].  The oxime was 
deprotonated using 2 equivalents of butyllithium followed by condensation with ethyl 
acetate.  The result, isoxazoline was treated with chlorosulfonic acid [9].  This was followed 
by the reaction of sulfonyl chloride with aqueous ammonia yielding valdecoxib [10].  
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FIGURE 1:  THE CYCLO-OXYGENASE AND LIPOOXYGENASE PATHWAY 
 
 
Source: Journal of Human Hypertension (2005) 19, 1–5. doi:10.1038/sj.jhh.1001777. 
Published online 23 September 2004 
 
2.2. Pharmacokinetics and metabolism 
In healthy young subjects, valdecoxib is well absorbed on an empty stomach and achieves 
maximum plasma concentrations in about 3 hours (Tmax). Approximately 83% of the drug 
reaches the systemic circulation and peak plasma concentration (Cmax) and concentration 
time curves (AUC) remain little affected by meals or concomitant antacid use  (Pharmacia 
corporation 2002). The Cmax and AUC show proportional increases with doses up to a 
maximum of 400mg with steady state concentrations being achieved after four days of 
treatment [11].   
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Valdecoxib is heavily protein bound with >98% of drug being bound to plasma proteins at 
plasma concentrations in the range of 21-2384 ug/L. The drug undergoes hepatic 
metabolism, metabolized by both the nonP450 and P450 cytochrome pathways (Figure 2).  
The P450 system is predominant with hydroxylation and aryl hydroxylation resulting in the 
formation of a carboxylic acid derivative via the CYP3A4, CYP2C9, and P450 enzyme systems. 
In contrast, the non P450 pathway glucuronidates the sulphonamide group.  The 
metabolites of valdecoxib are excreted in the urine with less than 5% of the drug being 
excreted unchanged in the urine [12]. 
The elimination half-life of valdecoxib is approximately 8-11 hours.   Plasma concentrations 
of valdecoxib were increased by 130% in patients with mild to moderate hepatic impairment 
(Child Pugh Class B). It is recommended that patients with hepatic impairment be monitored 
and commenced on smaller doses of treatment. However, the indication for using this drug 
in this vulnerable population must be re-examined and alternative options employed 
whenever possible. There are no studies of the use of valdecoxib in end-stage liver disease, 
but due to its pathways of metabolism valdecoxib is best avoided in severe liver disease[12].  
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FIGURE 2. METABOLISM OF VALDECOXIB 
 
 
Elderly persons have higher concentrations of valdecoxib in the circulation, attributed to the 
decline in hepatic and renal function as well as reduced volumes of distribution.  It is 
therefore recommended that the valdecoxib dose be reduced in the  elderly, especially 
those with reduced body weight <50kg [12].  
 
2.2 Pharmacodynamics 
Valdecoxib binds tightly in a relatively stable fashion to COX-2 thereby inhibiting its function.  
In vitro studies have demonstrated that valdecoxib potently inhibits prostaglandin E2 
production (50% inhibition of COX2 (IC50) =0.0005uM/L compared to COX -1 (IC50) =140uM) 
[12][13].  Similar results have been obtained in ex-vivo studies, in human whole blood, 
where the corresponding COX2 (IC50) and COX1 (Similar results have been obtained in ex-
vivo studies, in human whole blood, where the corresponding COX2 (IC50) were 0.89uM and 
25.4 uM/L respectively.  
7 | P a g e  
 
The COX1/COX2 inhibition ratios are much higher for valdecoxib when compared to 
celecoxib  [10] and the non-selective NSAIDs [14].  The primary metabolites of valdecoxib do 
not contribute significantly to the mechanism of action of valdecoxib.  Valdecoxib is also the 
active moiety of the parenteral COX2 selective inhibitor parecoxib sodium [15]. 
The analgesic effects of valdecoxib were studied in rat models of inflammation.  The dose of 
valdecoxib that caused a 50% reduction in inflammation was 0.05, 0.032 and 10.2 mg/kg in 
the carrageenan air pouch, adjuvant arthritis and carrageenan hind-paw models[10]. The 
analgesic effect on humans in described below in the clinical efficacy section. 
The traditional non-steroidal anti inflammatory drugs (tNSAIDS) inhibit platelet function.  
Double blind randomised control studies of the effect of valdecoxib 40mg twice daily on 
platelet function in healthy adults and elderly demonstrated that this drug does not affect 
platelet function or bleeding times [16, 17]. 
 
3.  Clinical efficacy 
The clinical efficacy of valdecoxib has been assessed in the treatment of osteoarthritis (OA) 
of knees, hips [18-20], rheumatoid arthritis [20], analgesia in dysmenorrhoea [21] and post-
operative analgesia after hip athroplasty [22],  orthopaedic foot and oral surgery [23][24].  A 
total of 4000 patients were evaluated in these studies. This review will focus on the patients 
with knee and hip osteoarthritis and rheumatoid arthritis. 
Valdecoxib has been more efficacious than placebo in treating osteoarthritis of the knee.  At 
higher doses (5mg b.i.d and 10mg once or b.i.d.), it was equally efficacious as naproxen 
500mg/bd. Assessment at week 1, 2 and 6 revealed an improvement in the patient 
assessment of pain, patient global assessment of arthritis (using visual analogue scores and 
the Western Ontario and Mc Masters Universities OA index) from baseline [25].  A double-
blind study of patients with moderate to severe knee OA revealed that valdecoxib 5mg b.i.d 
or 10mg b.i.d was equally efficacious as naproxen with fever endoscopically proven gastro-
duodenal ulcers at week 12 (3 vs 10% p<0.05) [18]. Valdecoxib has been similarly efficacious 
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in patients with hip OA, where the majority of studies compared valdecoxib with 
naproxen[19]. 
Valdecoxib 10mg, 20mg and 40mg q.d. has been compared with naproxen in the 
symptomatic treatment of patients with a flare of rheumatoid arthritis. The studies revealed 
that valdecoxib was well tolerated and as equally effective as naproxen 500mg b.i.d at doses 
of 20mg or 40mg q.d.[26, 27]. Similar results were shown when valdecoxib was compared to 
diclofenac [28] .However, it was noted that valdecoxib had superior gastrointestinal 
tolerability when compared to slow release diclofenac and ibuprofen [29]. The favourable 
gastrointestinal tolerance of valdecoxib has been further proven in a meta-analysis [30], 
where there was decrease in dyspepsia and improved drug tolerance in patients taking 
valdecoxib even at supra-therapeutic doses. 
Similar trends have been reported in the management of acute and chronic low back pain 
[31]. 
 
4. Safety and tolerability 
The gastrointestinal safety of valdecoxib has been proven in the studies discussed above.  It 
is clear that valdecoxib inhibits COX-2 enzyme to reduce prostaglandins E2 and I2 in 
inflamed joints without  affecting the COX-1 mediated, prostaglandin E2, I2 effected gastric 
mucosal protection [32].  
As COX-2 enzyme contributes to renal vasodilatory function by promoting prostacyclin 
generation in endothelial cells the renal safety of valdecoxib has been a cause for concern. 
The renal safety of valdecoxib has been explored in cohorts of patients with rheumatoid 
arthritis and osteoarthritis. The incidence of common renal side effects; albuminuria, 
peripheral oedema and hypertension following COX2 inhibition is higher than placebo 
(0.9%, 2.3% and 2.8% compared to 0.2%, 0.7% and 0.6% ) but is not significantly different to 
conventional NSAIDS (0.5%, 2.2%, and 1.5%) in pooled studies [33, 34][24, 25].  Studies of 
patients with severe renal dysfunction and those with end stage renal dysfunction on 
haemodialysis resulted in a 23% reduction of mean plasma clearance when compared with 
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healthy subjects. But, this is not of clinical significance to warrant a dosage reduction in 
renal insufficiency.  However, the use of valdecoxib in patients with advanced renal disease 
is strongly discouraged. The majority of renal effects are dose dependent and attributed to 
the occurrence of oedema and rise in blood pressure.  Therefore valdecoxib use in subjects 
dependent on the renin-angiotensin system haemodynamics; e.g cirrhotics, patients with 
congestive heart disease; must be accompanied by monitoring of renal function.  
Drug interactions between valdecoxib and many other drugs have been extensively studied 
[35, 36]. Of particular interest is the fact that valdecoxib does not significantly affect the 
action of methotrexate.  Short courses of low dose valdecoxib (10mg b.d.) had no effect on 
the pharmacokinetics of oral methotrexate.  Similar changes have been described with 
intramuscular methotrexate (unpublished reports).  However, there is little data on 
interactions between valdecoxib and other disease modifying drugs.  
 
5.  Regulatory affairs 
In 2005 the Food and Drug Administration agency of the United States Department of 
Health and Human Services (FDA) and the European Medicines Agency (EMEA) requested 
that the manufacturer voluntarily withdraw valdecoxib from the market due to its potential 
side effect profile. The lack of adequate data on the long-term safety of the drug, increased 
risk of adverse cardiovascular events in short term coronary artery bypass graft trials, 
reports of serious skin reactions coupled with the lack of any significant advantage over 
NSAIDS were cited as reasons for this withdrawal request. 
The increase in cardiovascular events has been attributed to its potent inhibition of COX-2 
and consequent reduction of prostacyclin biosynthesis. This fact is supported by in vivo 
studies which have demonstrated that NSAIDS (both the COX-2 inhibitors and some 
tNSAIDS) reduce systemic biosynthesis of prostacyclins in healthy humans by >60% [37].  
In the vascular system, prostacyclin formation in the endothelium is induced in response to 
platelet vessel wall interactions and haemodynamic stress [38-40].  There is evidence that 
prostacyclin binding to its receptor activates membrane bound adenyl-cyclase leading to 
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formation of cyclic AMP[41].  cAMP initiates inhibition of platelet aggregation, vascular 
smooth muscle constriction and induction of thrombomodulin which inhibits coagulation, 
with resultant reduction of vascular occlusion.  In addition, studies on rodent models have 
confirmed that prostacyclin helps prevent hypertension and cardiac hypertrophy [42, 43].  
Moreover, clinical trials of COX2 inhibitors used for other indications have demonstrated a 
trend that CV hazard is dose dependent [44, 45]. It is interesting that the magnitude of 
concomitant COX-1 inhibition mitigates the cardiovascular risk [46].  One explanation for 
this is believed to be the result of inhibition of thromboxane A2 (TXA2), another pro-
aggregatory agent [47].  It is noteworthy that cardiovascular risk is only minimized in these 
cases and is not completely abrogated. 
Another possible contributory factor to the cardiovascular risk is the occurrence of 
hypertension.  This adverse effect is attributed to the inhibition of COX2 in the kidneys.  In 
susceptible individuals, inhibition of vasodilatory renal prostacyclin leads to sodium 
retention, oedema and hypertension [48].  This is a feature of COX-2 inhibitors and certain 
tNSAIDS [49, 50], but is greater in COX-2 inhibitors [51] at high dose, as shown in the MEDAL 
(Multinational Etoricoxib vs Diclofenac Arthritis Long-term Program) and EDGE studies [52, 
53].  These study results suggest that thrombosis rather than hypertension is the main 
mechanism of cardiovascular risk. 
The increased risk of cardiovascular adverse events for valdecoxib was highlighted in two 
short-term multi centre, randomized, double blind, placebo controlled trials assessing the 
safety of the drug in coronary bypass grafting (CABG) patients. In these trials valdecoxib (or 
its prodrug parecoxib) were used in post-operative analgesia. COX-2 inhibitors such as 
valdecoxib are ideal candidates to provide for post-operative pain relief: these agents give 
pain relief without increasing bleeding (compared to tNSAIDS). This is particularly true for 
valdecoxib, where the pro-drug parecoxib is intravenously administered, and is therefore 
eminently useful in the early post-operative period.  
In the first study in 2003 [54], 1671 CABG patients were randomly allocated to receive 
intravenous parecoxib for a maximum of three days followed by oral valdecoxib till 
postoperative  day 10, or intravenous placebo and oral valdecoxib or intravenous and oral 
placebo throughout the trial period of 14 days (151 patients in the valdecoxib (40mg 
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bid)/parecoxib sodium (40mg bid) group with 151 in the placebo/placebo group).  The 
primary end-points were adverse events, including cardiovascular events, renal dysfunction, 
poor wound healing and peptic ulceration. The groups given valdecoxib with parecoxib or 
valdecoxib with placebo had significantly higher adverse events.  This was particularly true 
for cardiovascular events including myocardial infarction, cardiac arrest, stroke and 
pulmonary embolism.  These events were more frequent in the treatment group when 
compared to placebo with a risk ratio of 3.7 (95 %CI, 1.0 to 13.5; P=0.03).  
However, the drug doses used in this short-term trial designed for pain relief, were different 
to the convential doses of valdecoxib recommended for standard rheumatological practice. 
The doses of valdecoxib, and particularly that of parecoxib were supra therapeutic, leading 
to profound suppression of COX-2 activity. It is invariable that such profound prostacyclin 
suppression in a cohort of patients at high coronary risk caused a rapid increase in vascular 
and thrombotic events. 
The second multicenter, phase III, placebo-controlled, double-blind, randomized, parallel-
group trial CABG study assessed the risk of cardio-vascular events, renal dysfunction, peptic 
ulceration and wound infection in 462 patients [55]. Patients were allocated at a ratio of 2:1 
to parecoxib/valdecoxib or standard care (control) groups, respectively. Intravenous study 
drug (parecoxib) (40 mg) was administered within 30 minutes of extubation and at a dose of 
20mg IV b.i.d for a minimum of 3 days. Thereafter, oral treatment of valdecoxib 40 mg b.i.d. 
was initiated and continued for a total of 14 days. Clinical adverse events were assessed 
from the time of the first dose through the 30-day post-dosing period.  Though the 
parecoxib/valdecoxib groups had better pain relief than the control group during the study 
time points, serious adverse events were twice as frequent in the valdecoxib-parecoxib 
group, particular cardiovascular events. The incidences of other individual serious adverse 
events, including cerebrovascular complications and renal dysfunction, were proportionally 
greater, though not significantly different, between the groups. However, despite the lower 
doses of valdecoxib and the shorter treatment duration compared to the first study, 
parecoxib was used at a dose of 20mg b.i.d., which is still a supra-therapeutic dose 
completely suppressing COX-2 activity. 
Similar findings were obtained from a meta-analysis of the coronary and cerebrovascular 
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adverse events in these two CABG and other placebo controlled trials of valdecoxib in 
patients with arthritis demonstrated a threefold higher cardiovascular risk in valdecoxib 
compared to placebo (RR=3.08; 95%CI = 1.20-7.87) [56]  
However, this finding was not corroborated in a similar unpublished study on 1050 patients 
undergoing major general or orthopaedic surgery. These patients were given an initial dose 
of parecoxib 40mg i.v. followed by 20mg i.v. b.i.d for three days, followed by oral valdecoxib 
(20 mg b.i.d) (525 patients) or placebo (525 patients) for the 10 day treatment period or a 
placebo intravenous infusion followed by oral placebo (525 patients). No significant 
differences were detected in the overall safety profile [57]. 
These findings suggest that the CV effects of valdecoxib are most marked in patients with 
severe haemostatic activation. There are a multitude of potential contributors for this 
increased thrombotic risk.  Patients who are subject to CABG have inherently increased risk 
of CV complications affecting the cardiovascular, cerebrovascular, renal and intestinal 
systems.  In addition, platelet activation occurs early in the post-CABG patients [58] and may 
not be counteracted by aspirin. Moreover, valdecoxib potentially interferes with the COX-2 
mediated cardiac ischaemia protective effect of anaesthetics [59].  
It is believed that the contact between blood and synthetic surfaces in the extra-corporeal 
circuit activates platelets, endothelial cells and leucocytes with resultant thrombotic 
tendency [60][61]. Furthermore, the cardiopulmonary bypass increases prostacyclin and 
thromboxane levels [62, 63] In addition, cross clamping may contribute to ischaemic-
reperfusion insults to the myocardium [64].  The combination of these factors, which may 
be exponential, explain why CABG patients are more susceptible to the CV complications of 
valdecoxib.  The near total suppression of COX-2 inhibition, and subsequent thrombosis 
could not be mitigated by low dose aspirin.   The rapid suppression of vascular prostacyclin 
by intravenous parecoxib could not be countered by the orally administered aspirin, which 
requires at least an hour to supress platelet COX-1.  In addition, a high number of CABG 
patients are not-responsive to aspirin in the immediate post surgical period [65, 66].  This 
may be a consequence of the intense inflammatory cascade activation due to reperfusion of 
vital organs.  This may induce thromboxane synthesis through COX-2 induction in platelet-
leucocyte aggregates reducing the ability of aspirin to suppress thromboxane [67]. 
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Furthermore, there may be de-novo synthesis of COX-1 in the platelets activated by pro-
aggregatory stimuli which counteracts aspirin inhibition of platelet thromboxane 
biosynthesis [68]. 
There are no large scale RCTs performed which assess the safety of valdecoxib in OA or RA. 
There are unpublished data of 10 RCT in OA and RA where 4531 patients in total received 
valdecoxib.  The doses ranged from 10-80mg with a wide treatment duration of 6-52 weeks.  
It is noteworthy that the majority of these patients received valdecoxib for <12 weeks.  The 
incidence of serious CV events in patients of valdecoxib, or placebo (n=1142) or tNSAID 
(n=2261) were compared.  There was no significant difference between the exposure 
adjusted incidence of adverse events of or CV events when the three groups were 
compared.  However, as most of the studies were of short duration, and were inadequately 
powered to detect cardiovascular events in a lower CV risk group, the validity of this 
information is questionable [57]. 
Systematic review and meta-analyses have been performed to estimate the risk of MI 
associated with COX-2 inhibitors compared with placebo. Chen et al used a fixed- effect 
model to analyse 55 RCTs of 99,087 patients to estimate the odds ratio of MI associated 
with COX-2 inhibitors when compared to placebo, tNSAIDS and other COX-2 inhibitors.  The 
overall odds ratio for MI risk for COX-2 inhibitors was 1.46 (95% CI=1.02, 2.09). Celecoxib, 
Rofecoxib, Etoricoxib, Valdecoxib and Lumiracoxib were associated with higher MI risks 
compared to placebo though subgroup comparisons failed to achieve conventional levels of 
significance. The pooled OR for any COX-2 inhibitor compared to other tNSAIDS was 1.45 ( 
95% CI=1.09, 1.93).  Interestingly, valdecoxib had a lower MI risk than diclofenac (OR=0.14; 
95% CI=0.03, 0.73), though diclofenac continues to be used extensively. The available head-
to-head comparisons of COX-2 inhibitors failed to identify any difference in risk of MI 
between the different COX-2 inhibitors [69]. 
Similar results were yielded by the meta-analysis done by Kearney et al, with some 
significant new developments [70].  Data from 138 randomized trials involving 145,373 
participants were evaluated in this meta-analysis.  Trials for this meta-analysis were selected 
if they had at least 4 weeks scheduled treatment and included a comparison of a COX-2 
inhibitor versus placebo or versus a tNSAID.  This meta-analysis explored the following pre-
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specified outcomes: a serious vascular event, fatal/non-fatal myocardial infarction, 
fatal/non-fatal stroke or vascular death. Due to the hypothesis that naproxen has aspirin-
like antiplatelet effects the analysis of COX-2 inhibitor versus tNSAIDS were subdivided to 
naproxen and non-naproxen like NSAIDS. In placebo comparisons, the use of a selective 
COX-2 inhibitor was associated with a 42% increased incidence of serious vascular events 
(1.2% per year vs 0.9% per year; rate ratio 1.42 95% relative increase in the incidence of 
serious vascular events 1.13-1.78: P=0.0003.) This was chiefly attributed to increased 
incidence of myocardial infarction (0.6% yearly versus 0.3% year; 1.86, 1.33 to 2.59; 
P=0.0003).  There was no significant heterogeneity amongst the different types of COX-2 
inhibitors, though the data was inadequately powered to detect a real difference. High dose 
regimens of some tNSAIDS, i.e. ibuprofen and diclofenac had a similar risk of serious 
vascular events to COX-2 inhibitors (0.9% yearly versus 1% yearly, rate ratio 1.16, 0.97 to 
1.38; P=0.1). A marked difference in heterogeneity was detected when COX-2 inhibitors 
were compared with naproxen and non-naproxen tNSAIDS.  The explanation for these 
results is the profound inhibitory effect both tNSAIDS and COX-2 inhibitors on prostacyclin is 
unopposed by platelet COX-1 inhibition.  High dose naproxen inhibits both COX-1 in 
platelets and COX-2 in inflammatory tissues reducing the possibility of increased CV risk. As 
indicated before, valdecoxib and fellow COX-2 inhibitors suffer from only inhibiting COX-2 
mediated prostacyclin synthesis.  The platelet COX-1 remains functional with a propensity 
for thrombosis leading to thrombotic risk. [71]. 
Another cause for concern in the use of Valdecoxib is the risk of serious skin infections.  
Despite lacking the aromatic amine portion of sulphonamide usually implicated in toxic 
epidermal necrolysis (TEN), post-marketing surveillance of Valdecoxib demonstrated an 
increase of TEN, Steven Johnson Syndrome and Erythema multiforme [72, 73].  The arbitrary 
nature of Valdecoxib skin-reactions are of particular concern: they occur in patients with 
and without previous sulphonamide allergy and after short or long term use [72][73].  The 
skin reactions reported in valdecoxib ranged from widespread erythema to target lesions 
and TEN.  However, a more recent retrospective analysis of some of the reported skin 
reactions revealed that cutaneous effects of valdecoxib are distinctly different to TEN [74].   
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6. Expert Opinion 
Valdecoxib is an efficacious drug. It, like other COX-2 inhibitors,  is particularly useful in 
rheumatological practice, due to its superior gastrointestinal tolerability.  Gastroprotection 
is especially important as most patients with rheumatological disease are on multiple drugs, 
including disease modifying drugs, which cause gastrointestinal adverse effects.  In addition, 
most patients require anti-inflammatory medication frequently, and occasionally as a long 
term therapeutic option.  The presence of an injectable pro-drug, extends the usefulness of 
valdecoxib.  There is potential for use in rheumatology patients  with disease flares in the 
immediate post-operative period . 
It is unfortunate that this main advantage of valdecoxib, the presence of a parenterally 
administered pro-drug, led to its trials on a group of patients at particularly high risk of 
cardiovascular events. In addition, the subjects for these trials were patients immediately 
after post coronary bypass graft surgery:  circumstances with exaggerated propensity for 
thrombosis and vascular occlusion. Moreover, valdecoxib was used in supra-therapeutic 
doses, with the use of its parenteral drug, parecoxib. The doses used in both these trials are 
much higher than those used in rheumatological practice, or those trialled in the 
rheumatology treatment trials.  This dosage results in profound suppression of COX-2 
pathways. The results obtained are therefore of little surprise.  However, it is possible, 
though it will never be formally proven, that the cardiovascular risk will be attenuated in 
patients in whom valdecoxib would have been used in clinical practice, at the customary 
dosage. 
Similar findings have been highlighted for celecoxib (75). Despite its increased 
cardiovascular risk highlighted in patients with colorectal continues to be used extensively in 
clinical practice. The attenuated cardiovascular risk may be attributed the circumstances 
under which the drug was used (43).  
In our opinion, these trials have questioned the long-term safety not only of valdecoxib, but 
also of other COX-2 inhibitors, which should by virtue of mechanism of action result in a 
higher thrombotic risk. The fact that only rofecoxib and valdecoxib were selected for 
withdrawal warrants further discussion.  The fate of valdecoxib, in particular, was sealed by 
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reports of potentially life threatening skin reactions, the validity of these findings have been 
subsequently questioned (74). It is clear that valdecoxib, apart from having an injectable 
prodrug, has no other advantages over the other COX-2 inhibitors.  Therefore, there is 
currently little justification for the continued use of the drug. However, there are lessons to 
be learned from the processes that lead to the withdrawal of the drug. The need for caution 
in extrapolating the findings of trials to different patient subpopulations is highlighted from 
the unfortunate plight of valdecoxib. 
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